Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

glioma-associated peptide-loaded dendritic cell vaccine SL-701

A cell-based cancer vaccine comprised of dendritic cells (DCs) pulsed with various synthetic glioma-associated antigen (GAA) peptides, with potential antineoplastic activity. Upon subcutaneous administration, the glioma-associated peptide-loaded DC vaccine SL-701 exposes the immune system to various GAA peptides. This may stimulate both anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against the GAA-expressing glioma cells, which may result in tumor cell lysis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	SL-701

glioma-associated peptide-loaded dendritic cell vaccine SL-701

Search NCI's Drug Dictionary